How to Improve the Quality of Life of Patients with Prostate Cancer Treated with Hormone Therapy?

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. 2021;71(3):209–249. doi:10.3322/caac.21660
   Web of Science ®Google Scholar
• National Cancer Institute. Cancer Stat Facts: Prostate Cancer. Available from: https://seer.cancer.gov/statfacts/html/prost.html. Accessed January 8, 2023.
   Google Scholar
• Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–297.
   Google Scholar
• Schaeffer E, Srinivas S, Antonarakis ES, et al. NCCN guidelines insights: prostate cancer, version 1.2021. JNCCN. 2021;19(2):134–143.
   Google Scholar
• Mottet N, Cornford P, van den Bergh RCN. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer update; 2022.
   Google Scholar
• Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med. 2000;132(7):566–577. doi:10.7326/0003-4819-132-7-200004040-00009
   PubMed Web of Science ®Google Scholar
• Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339(15):1036–1042. doi:10.1056/NEJM199810083391504
   PubMed Web of Science ®Google Scholar
• Gillatt D. Antiandrogen treatments in locally advanced prostate cancer: are they all the same? J Cancer Res Clin Oncol. 2006;132(Suppl 1):S17–S26. doi:10.1007/s00432-006-0133-5
   PubMedGoogle Scholar
• Wadosky KM, Koochekpour S. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Oncotarget. 2016;7(39):64447–64470. doi:10.18632/oncotarget.10901
   PubMedGoogle Scholar
• James ND, de Bono JS, Spears MR, et al.; STAMPEDE Investigators. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–351. doi:10.1056/NEJMoa1702900
   PubMed Web of Science ®Google Scholar
• Chi KN, Agarwal N, Bjartell A, Chung BH; TITAN Investigators. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13–24. doi:10.1056/NEJMoa1903307
   PubMed Web of Science ®Google Scholar
• Davis ID, Martin AJ, Stockler MR; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121–131. doi:10.1056/NEJMoa1903835
   PubMed Web of Science ®Google Scholar
• Fizazi K, Shore N, Tammela TL, et al.; ARAMIS Investigators. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380(13):1235–1246. doi:10.1056/NEJMoa1815671
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, et al.; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005. doi:10.1056/NEJMoa1014618
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, de Bono JS; COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138–148. doi:10.1056/NEJMoa1209096
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al.; AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–1197. doi:10.1056/NEJMoa1207506
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, et al.; PREVAIL Investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–433. doi:10.1056/NEJMoa1405095
   PubMed Web of Science ®Google Scholar
• Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378(26):2465–2474. doi:10.1056/NEJMoa1800536
   PubMed Web of Science ®Google Scholar
• Smith MR, Saad F, Chowdhury S, et al.; SPARTAN Investigators. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15):1408–1418. doi:10.1056/NEJMoa1715546
   PubMed Web of Science ®Google Scholar
• Fizazi K, Tran N, Fein L, et al.; LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–360. doi:10.1056/NEJMoa1704174
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974–2986. doi:10.1200/JCO.19.00799
   PubMed Web of Science ®Google Scholar
• Attard G, Murphy L, Clarke NW, et al.; Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399(10323):447–460. doi:10.1016/S0140-6736(21)02437-5
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Azad AA, Iguchi T, et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2022;40(15):1616–1622. doi:10.1200/JCO.22.00193
   PubMed Web of Science ®Google Scholar
• Kokorovic A, So AI, Serag H, et al. Canadian Urological Association guideline on androgen deprivation therapy: adverse events and management strategies. Can Urol Assoc J. 2021;15(6):E307–E322. doi:10.5489/cuaj.7355
   PubMed Web of Science ®Google Scholar
• Pyrgidis N, Vakalopoulos I, Sountoulides P. Endocrine consequences of treatment with the new androgen receptor axis-targeted agents for advanced prostate cancer. Hormones. 2021;20(1):73–84. doi:10.1007/s42000-020-00251-5
   PubMedGoogle Scholar
• Tucci M, Leone G, Buttigliero C, et al. Hormonal treatment and quality of life of prostate cancer patients: new evidence. Minerva urologica e nefrologica. 2018;70(2):144–151. doi:10.23736/S0393-2249.17.03066-1
   PubMed Web of Science ®Google Scholar
• Elmehrath AO, Afifi AM, Al-Husseini MJ, et al. Causes of death among patients with metastatic prostate cancer in the US From 2000 to 2016. JAMA Netw Open. 2021;4(8):e2119568. doi:10.1001/jamanetworkopen.2021.19568
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhu S, Sun L, et al. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. PLoS One. 2014;9(9):e107516. doi:10.1371/journal.pone.0107516
   PubMed Web of Science ®Google Scholar
• Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol. 2015;68(3):386–396. doi:10.1016/j.eururo.2014.11.039
   PubMed Web of Science ®Google Scholar
• Nguyen PL, Je Y, Schutz FA, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011;306(21):2359–2366. doi:10.1001/jama.2011.1745
   PubMed Web of Science ®Google Scholar
• Bosco C, Crawley D, Adolfsson J, Rudman S, Van Hemelrijck M. Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis. PLoS One. 2015;10(3):e0117344. doi:10.1371/journal.pone.0117344
   PubMed Web of Science ®Google Scholar
• Hak AE, Witteman JC, de Jong FH, Geerlings MI, Hofman A, Pols HA. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab. 2002;87(8):3632–3639. doi:10.1210/jcem.87.8.8762
   PubMed Web of Science ®Google Scholar
• O’Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2015;33(11):1243–1251. doi:10.1200/JCO.2014.59.1792
   PubMed Web of Science ®Google Scholar
• Ziehr DR, Chen MH, Zhang D, et al. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int. 2015;116(3):358–365. doi:10.1111/bju.12905
   PubMed Web of Science ®Google Scholar
• D’Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25(17):2420–2425. doi:10.1200/JCO.2006.09.3369
   PubMed Web of Science ®Google Scholar
• Knutsson A, Hsiung S, Celik S, et al. Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE(-/-) mice. Sci Rep. 2016;6:26220. doi:10.1038/srep26220
   PubMed Web of Science ®Google Scholar
• Hopmans SN, Duivenvoorden WC, Werstuck GH, Klotz L, Pinthus JH. GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model. Urol Oncol. 2014;32(8):1126–1134. doi:10.1016/j.urolonc.2014.06.018
   PubMed Web of Science ®Google Scholar
• Tisseverasinghe S, Tolba M, Saad F, Gravis G, Bahoric B, Niazi T. Should prostate cancer patients with history of cardiovascular events be preferentially treated with luteinizing hormone-releasing hormone antagonists? J Clin Oncol. 2022;40(36):4173–4177. doi:10.1200/JCO.22.00883
   PubMed Web of Science ®Google Scholar
• Margel D, Peer A, Ber Y, et al. Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease. J Urol. 2019;202(6):1199–1208. doi:10.1097/JU.0000000000000384
   PubMed Web of Science ®Google Scholar
• Shore ND, Saad F, Cookson MS, et al.; HERO Study Investigators. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020;382(23):2187–2196. doi:10.1056/NEJMoa2004325
   PubMed Web of Science ®Google Scholar
• Lopes RD, Higano CS, Slovin SF, et al.; PRONOUNCE Study Investigators. Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. Circulation. 2021;144(16):1295–1307. doi:10.1161/CIRCULATIONAHA.121.056810
   PubMed Web of Science ®Google Scholar
• Berruti A, Dogliotti L, Terrone C, et al.; Gruppo Onco Urologico Piemontese (G.O.U.P.), Rete Oncologica Piemontese. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol. 2002;167(6):2361–2367. doi:10.1016/S0022-5347(05)64985-3
   PubMed Web of Science ®Google Scholar
• Haseen F, Murray LJ, Cardwell CR, O’Sullivan JM, Cantwell MM. The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis. J Cancer Surviv. 2010;4(2):128–139. doi:10.1007/s11764-009-0114-1
   PubMed Web of Science ®Google Scholar
• Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87(2):599–603. doi:10.1210/jcem.87.2.8299
   PubMed Web of Science ®Google Scholar
• Cheung AS, Tinson AJ, Milevski SV, Hoermann R, Zajac JD, Grossmann M. Persisting adverse body composition changes 2 years after cessation of androgen deprivation therapy for localised prostate cancer. Eur J Endocrinol. 2018;179(1):21–29. doi:10.1530/EJE-18-0117
   PubMed Web of Science ®Google Scholar
• Nobes JP, Langley SE, Klopper T, Russell-Jones D, Laing RW. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int. 2012;109(10):1495–1502. doi:10.1111/j.1464-410X.2011.10555.x
   PubMed Web of Science ®Google Scholar
• He K, Hu H, Ye S, Wang H, Cui R, Yi L. The effect of metformin therapy on incidence and prognosis in prostate cancer: a systematic review and meta-analysis. Sci Rep. 2019;9(1):2218. doi:10.1038/s41598-018-38285-w
   PubMed Web of Science ®Google Scholar
• Jayalath VH, Clark R, Katherine Lajkosz NE, Hamilton RJ, Hamilton RJ. Statin use and survival in men receiving androgen-ablative therapies for advanced prostate cancer: a systematic review and meta-analysis of cohort studies. J Clin Oncol. 2022;40(6_suppl):83. doi:10.1200/JCO.2022.40.6_suppl.083
   PubMed Web of Science ®Google Scholar
• Gagliano-Jucá T, Travison TG, Kantoff PW, et al. Androgen deprivation therapy is associated with prolongation of QTc Interval in men with prostate cancer. J Endocr Soci. 2018;2(5):485–496. doi:10.1210/js.2018-00039
   PubMed Web of Science ®Google Scholar
• Iacovelli R, Ciccarese C, Bria E, et al. The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clin Genitourin Cancer. 2018;16(3):e645–e653. doi:10.1016/j.clgc.2017.12.007
   PubMed Web of Science ®Google Scholar
• Moreira RB, Debiasi M, Francini E, et al. Differential side effects profile in patients with mCRPC treated with Abiraterone or enzalutamide: a meta-analysis of randomized controlled trials. Oncotarget. 2017;8(48):84572–84578. doi:10.18632/oncotarget.20028
   PubMedGoogle Scholar
• Astellas Pharma Canada Inc. XTANDI® product monograph. Markham, Ontario; 2013.
   Google Scholar
• Shigehara K, Izumi K, Kadono Y, Mizokami A. Testosterone and bone health in men: a narrative review. J Clin Med. 2021;10(3):530. doi:10.3390/jcm10030530
   PubMed Web of Science ®Google Scholar
• Clarke BL, Khosla S. Androgens and bone. Steroids. 2009;74(3):296–305. doi:10.1016/j.steroids.2008.10.003
   PubMed Web of Science ®Google Scholar
• Cianferotti L, Bertoldo F, Carini M, et al. The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation. Oncotarget. 2017;8(43):75646–75663. doi:10.18632/oncotarget.17980
   PubMedGoogle Scholar
• Bargiota A, Oeconomou A, Zachos I, Samarinas M, Pisters L, Tzortzis V. Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on muscle and bone health. JBUON. 2020;25(3):1286–1294.
   Google Scholar
• Edmunds K, Tuffaha H, Scuffham P, Galvão DA, Newton RU. The role of exercise in the management of adverse effects of androgen deprivation therapy for prostate cancer: a rapid review. Support Care Cancer. 2020;28(12):5661–5671. doi:10.1007/s00520-020-05637-0
   PubMed Web of Science ®Google Scholar
• Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer. 2009;115(11):2388–2399. doi:10.1002/cncr.24283
   PubMed Web of Science ®Google Scholar
• Wang A, Obertová Z, Brown C, et al. Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand. BMC Cancer. 2015;15:837. doi:10.1186/s12885-015-1843-3
   PubMed Web of Science ®Google Scholar
• Cheung AS, Pattison D, Bretherton I, et al. Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines. Andrology. 2013;1(4):583–589. doi:10.1111/j.2047-2927.2013.00093.x
   PubMed Web of Science ®Google Scholar
• Bienz M, Saad F. Androgen-deprivation therapy and bone loss in prostate cancer patients: a clinical review. Bonekey Rep. 2015;4:716. doi:10.1038/bonekey.2015.85
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Wagner J, Nelson JB, Perera S, Britton C, Resnick NM. Vertebral fractures and trabecular microstructure in men with prostate cancer on androgen deprivation therapy. J Bone Miner Res. 2013;28(2):325–332. doi:10.1002/jbmr.1771
   PubMed Web of Science ®Google Scholar
• Santini D, Berruti A, Di Maio M, et al. Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion. ESMO Open. 2020;5(2):e000652. doi:10.1136/esmoopen-2019-000652
   PubMed Web of Science ®Google Scholar
• Coleman R, Hadji P, Body JJ, et al.; ESMO Guidelines Committee. Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2020;31(12):1650–1663. doi:10.1016/j.annonc.2020.07.019
   PubMed Web of Science ®Google Scholar
• Turco F, Tucci M, Buttigliero C. Adverse event assessment in prostate cancer patients receiving androgen deprivation therapy: are we doing enough? Minerva Urol Nephrol. 2021;73(6):870–872. doi:10.23736/S2724-6051.21.04817-5
   PubMedGoogle Scholar
• Smith MR, Egerdie B, Hernández Toriz N; Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745–755. doi:10.1056/NEJMoa0809003
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R; Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458–1468. doi:10.1093/jnci/94.19.1458
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813–822. doi:10.1016/S0140-6736(10)62344-6
   PubMed Web of Science ®Google Scholar
• Kim SH, Joung JY, Kim S, et al. Comparison of bone mineral loss by combined androgen block agonist versus GnRH in patients with prostate cancer: a 12 month-prospective observational study. Sci Rep. 2017;7:39562. doi:10.1038/srep39562
   PubMed Web of Science ®Google Scholar
• Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013;368(14):1314–1325. doi:10.1056/NEJMoa1212299
   PubMed Web of Science ®Google Scholar
• Roubaud G, Kostine M, Raymond S. Bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without Abiraterone plus prednisone in the PEACE-1 phase 3 trial. J Clin Oncol. 2022;40(6_suppl):19. doi:10.1200/JCO.2022.40.6_suppl.019
   Google Scholar
• Wu LM, Tanenbaum ML, Dijkers MP, et al. Cognitive and neurobehavioral symptoms in patients with non-metastatic prostate cancer treated with androgen deprivation therapy or observation: a mixed methods study. Soc Sci Med. 2016;156:80–89. doi:10.1016/j.socscimed.2016.03.016
   PubMed Web of Science ®Google Scholar
• Wu LM, Diefenbach MA, Gordon WA, Cantor JB, Cherrier MM. Cognitive problems in patients on androgen deprivation therapy: a qualitative pilot study. Urol Oncol. 2013;31(8):1533–1538. doi:10.1016/j.urolonc.2012.07.003
   PubMed Web of Science ®Google Scholar
• McGinty HL, Phillips KM, Jim HS, et al. Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Support Care Cancer. 2014;22(8):2271–2280. doi:10.1007/s00520-014-2285-1
   PubMed Web of Science ®Google Scholar
• Gonzalez BD, Jim HS, Booth-Jones M, et al. Course and predictors of cognitive function in patients with prostate cancer receiving androgen-deprivation therapy: a controlled comparison. J Clin Oncol. 2015;33(18):2021–2027. doi:10.1200/JCO.2014.60.1963
   PubMed Web of Science ®Google Scholar
• Siebert AL, Lapping-Carr L, Morgans AK. Neuropsychiatric impact of androgen deprivation therapy in patients with prostate cancer: current evidence and recommendations for the clinician. Eur Urol Focus. 2020;6(6):1170–1179. doi:10.1016/j.euf.2020.05.014
   PubMedGoogle Scholar
• Sari Motlagh R, Quhal F, Mori K, et al. The risk of new onset dementia and/or Alzheimer disease among patients with prostate cancer treated with androgen deprivation therapy: a systematic review and meta-analysis. J Urol. 2021;205(1):60–67. doi:10.1097/JU.0000000000001341
   PubMed Web of Science ®Google Scholar
• Finley SK, Kritzer MF. Immunoreactivity for intracellular androgen receptors in identified subpopulations of neurons, astrocytes and oligodendrocytes in primate prefrontal cortex. J Neurobiol. 1999;40(4):446–457. doi:10.1002/(SICI)1097-4695(19990915)40:4<446::AID-NEU3>3.0.CO;2-J
   PubMedGoogle Scholar
• Verdile G, Laws SM, Henley D, et al.; AIBL Research Group. Associations between gonadotropins, testosterone and β amyloid in men at risk of Alzheimer’s disease. Mol Psychiatry. 2014;19(1):69–75. doi:10.1038/mp.2012.147
   PubMed Web of Science ®Google Scholar
• Marandino L, Vignani F, Buttigliero C, et al. Evaluation of cognitive function in trials testing new-generation hormonal therapy in patients with prostate cancer: a systematic review. Cancers. 2020;12(9):2568. doi:10.3390/cancers12092568
   PubMed Web of Science ®Google Scholar
• Wefel JS, Ryan CJ, Van J, Jackson JC, Morgans AK. Assessment and management of cognitive function in patients with prostate cancer treated with second-generation androgen receptor pathway inhibitors. CNS Drugs. 2022;36(5):419–449. doi:10.1007/s40263-022-00913-5
   PubMed Web of Science ®Google Scholar
• Thiery-Vuillemin A, Poulsen MH, Lagneau E, et al.; AQUARiUS Investigators. Impact of abiraterone acetate plus prednisone or enzalutamide on patient-reported outcomes in patients with metastatic castration-resistant prostate cancer: final 12-mo analysis from the observational AQUARiUS study. Eur Urol. 2020;77(3):380–387. doi:10.1016/j.eururo.2019.09.019
   PubMed Web of Science ®Google Scholar
• Shore ND, Saltzstein D, Sieber P, et al. Results of a Real-World Study of Enzalutamide And Abiraterone Acetate With Prednisone Tolerability (REAAcT). Clin Genitourin Cancer. 2019;17(6):457–463.e6. doi:10.1016/j.clgc.2019.07.017
   PubMed Web of Science ®Google Scholar
• Shore ND, Antonarakis ES, Cookson MS, et al. Optimizing the role of androgen deprivation therapy in advanced prostate cancer: challenges beyond the guidelines. Prostate. 2020;80(6):527–544. doi:10.1002/pros.23967
   PubMed Web of Science ®Google Scholar
• Sparasci D, Napoli I, Rossi L, et al. Prostate cancer and sleep disorders: a systematic review. Cancers. 2022;14(7):1784. doi:10.3390/cancers14071784
   PubMed Web of Science ®Google Scholar
• Jones JM, Kohli M, Loprinzi CL. Androgen deprivation therapy-associated vasomotor symptoms. Asian J Androl. 2012;14(2):193–197. doi:10.1038/aja.2011.101
   PubMed Web of Science ®Google Scholar
• Crook JM, O’Callaghan CJ, Duncan G, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med. 2012;367(10):895–903. doi:10.1056/NEJMoa1201546
   PubMed Web of Science ®Google Scholar
• Rhee H, Gunter JH, Heathcote P, et al. Adverse effects of androgen-deprivation therapy in prostate cancer and their management. BJU Int. 2015;115(Suppl 5):3–13. doi:10.1111/bju.12964
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med. 1994;331(6):347–352. doi:10.1056/NEJM199408113310602
   PubMed Web of Science ®Google Scholar
• Irani J, Salomon L, Oba R, Bouchard P, Mottet N. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol. 2010;11(2):147–154. doi:10.1016/S1470-2045(09)70338-9
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Dueck AC, Khoyratty BS, et al. A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). Ann Oncol. 2009;20(3):542–549. doi:10.1093/annonc/mdn644
   PubMed Web of Science ®Google Scholar
• Ashamalla H, Jiang ML, Guirguis A, Peluso F, Ashamalla M. Acupuncture for the alleviation of hot flashes in men treated with androgen ablation therapy. Int J Radiat Oncol Biol Phys. 2011;79(5):1358–1363.
   PubMed Web of Science ®Google Scholar
• Calais da Silva FE, Bono AV, Whelan P. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol. 2009;55(6):1269–1277. doi:10.1016/j.eururo.2009.02.016
   PubMed Web of Science ®Google Scholar
• Nguyen PL, Alibhai SM, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67(5):825–836. doi:10.1016/j.eururo.2014.07.010
   PubMed Web of Science ®Google Scholar
• Higano CS. Sexuality and intimacy after definitive treatment and subsequent androgen deprivation therapy for prostate cancer. J Clin Oncol. 2012;30(30):3720–3725. doi:10.1200/JCO.2012.41.8509
   PubMed Web of Science ®Google Scholar
• Storey DJ, McLaren DB, Atkinson MA, et al. Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy. Ann Oncol. 2012;23(6):1542–1549. doi:10.1093/annonc/mdr447
   PubMed Web of Science ®Google Scholar
• Ternov KK, Sønksen J, Fode M, et al. Fatigue, health-related quality-of-life and metabolic changes in men treated with enzalutamide or Abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer: a randomised clinical trial (HEAT). Eur J Cancer. 2022;171:75–84. doi:10.1016/j.ejca.2022.04.034
   PubMed Web of Science ®Google Scholar
• Cormie P, Zopf EM. Exercise medicine for the management of androgen deprivation therapy-related side effects in prostate cancer. Urol Oncol. 2020;38(2):62–70. doi:10.1016/j.urolonc.2018.10.008
   PubMed Web of Science ®Google Scholar
• Baguley BJ, Skinner TL, Jenkins DG, Wright ORL. Mediterranean-style dietary pattern improves cancer-related fatigue and quality of life in men with prostate cancer treated with androgen deprivation therapy: a pilot randomised control trial. Clinical Nutr. 2021;40(1):245–254. doi:10.1016/j.clnu.2020.05.016
   PubMed Web of Science ®Google Scholar
• Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab. 2008;93(3):914–919. doi:10.1210/jc.2007-1692
   PubMed Web of Science ®Google Scholar
• Grossmann M, Zajac JD. Hematological changes during androgen deprivation therapy. Asian J Androl. 2012;14(2):187–192. doi:10.1038/aja.2011.102
   PubMed Web of Science ®Google Scholar
• Corona G, Filippi S, Comelio P, et al. Sexual function in men undergoing androgen deprivation therapy. Int J Impot Res. 2021;33(4):439–447. doi:10.1038/s41443-021-00418-7
   PubMed Web of Science ®Google Scholar
• Lapi F, Azoulay L, Niazi MT, Yin H, Benayoun S, Suissa S. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer. JAMA. 2013;310(3):289–296. doi:10.1001/jama.2013.8638
   PubMed Web of Science ®Google Scholar
• Ng E, Woo HH, Turner S, Leong E, Jackson M, Spry N. The influence of testosterone suppression and recovery on sexual function in men with prostate cancer: observations from a prospective study in men undergoing intermittent androgen suppression. J Urol. 2012;187(6):2162–2166. doi:10.1016/j.juro.2012.01.080
   PubMed Web of Science ®Google Scholar
• Saltalamacchia G, Frascaroli M, Bernardo A, Quaquarini E. Renal and cardiovascular toxicities by new systemic treatments for prostate cancer. Cancers. 2020;12(7):1750. doi:10.3390/cancers12071750
   PubMed Web of Science ®Google Scholar
• Attard G, Reid AH, Auchus RJ, et al. Clinical and biochemical consequences of CYP17A1 inhibition with Abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab. 2012;97(2):507–516. doi:10.1210/jc.2011-2189
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Annex 1- Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/zytiga-epar-product-information_en.pdf. Accessed January 8, 2023.
   Google Scholar
• European Medicines Agency. Part VI: Summary of the Risk Management Plan. Available from: https://www.ema.europa.eu/en/documents/rmp-summary/erleada-epar-risk-management-plan-summary_en.pdf. Accessed January 8, 2023.
   Google Scholar
• European Medicines Agency. Summary of Risk Management Plan (RMP) for NUBEQA® (darolutamide). Available from: https://www.ema.europa.eu/en/documents/rmp-summary/nubeqa-epar-risk-management-plan-summary_en.pdf. Accessed January 8, 2023.
   Google Scholar
• Smith MR, Hussain M, Saad F, et al.; ARASENS Trial Investigators. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386(12):1132–1142. doi:10.1056/NEJMoa2119115
   PubMed Web of Science ®Google Scholar
• Fowler FJ Jr, McNaughton Collins M, Walker Corkery E, Elliott DB, Barry MJ. The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma. Cancer. 2002;95(2):287–295. doi:10.1002/cncr.10656
   PubMed Web of Science ®Google Scholar
• Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36(5):446–453. doi:10.1200/JCO.2017.75.4853
   PubMed Web of Science ®Google Scholar
• Phillips R, Shi WY, Deek M, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6(5):650–659. doi:10.1001/jamaoncol.2020.0147
   PubMed Web of Science ®Google Scholar
• Deek MP, Van der Eecken K, Sutera P, et al. Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials. J Clin Oncol. 2022;40(29):3377–3382. doi:10.1200/JCO.22.00644
   PubMed Web of Science ®Google Scholar